Transplantation with histocompatible identical siblings is a curative treatment for patients with myelodysplastic syndromes (MDS).
Introduction
Myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders with different clinical and morphological characteristics. 1, 2 These syndromes are characterized by progressive refractory cytopenias with dysplastic features in blood and bone marrow and defective myeloid maturation. Secondary MDS may develop after exposure to chemotherapy, alkylating agents and radiation therapy (therapy-related MDS). 3, 4 MDS are clonal diseases, often associated with chromosomal abnormalities. 5 The clinical course of MDS varies from a quiescent form to a rapidly fatal disease. Various methods, such as the International Prognostic Scoring System (IPSS) 6 have been developed to predict the prognosis of patients with MDS.
As the majority of patients with MDS are elderly, most receive supportive therapy in the form of antibiotics, growth factors, and in blood products. 7 The most effective curative treatment of MDS is allogeneic stem cell transplantation. Prognostic factors have been recognized which can predict better outcome after chemotherapy or transplantation, such as younger age and early stage of disease. 8 The best results have been obtained using genotypically HLA-identical sibling donors. Unfortunately, most patients do not have a genotypically HLA-identical sibling. However, alternative donors include nonidentical family members or unrelated donors. Autologous stem cell transplantation (ASCT) is also increasingly used with encouraging results. 9 The MDS Subcommittee of the Chronic Leukemia Working Party (CLWP) of the European Group for Blood and Marrow Transplantation (EBMT) evaluated the outcome of patients transplanted using nonidentical family donors. We analyzed several prognostic factors including age, stage of disease, family relationship and number of HLA mismatches. In addition, we compared the results of transplantation with nonidentical family donors to those obtained by transplantation with unrelated donors or autologous stem cells.
Patients and methods

Study population
The CLWP of the EBMT has collected data on 79 patients who underwent allogeneic bone marrow transplantation from genotypically nonidentical family donors for the treatment of MDS or secondary AML. Syngeneic and genotypically identical siblings have been excluded from this study. Histocompatible siblings were considered genotypically identical when serological and molecular typing did not disclose any HLA difference between patient and donor. The donors have been divided into three categories: siblings, parents and other family members. Twenty-seven donors were siblings, 24 were parents, and 25 were other family members. Twenty-one of the 79 donors were phenotypically identical. The remaining 58 donors were mismatched for one or more HLA antigens.
Patients
Median age of the 79 patients transplanted using genotypically nonidentical family donors was 32 years (range 0-59 years). Forty-five patients were male and 34 patients were female. Table 1 presents the disease classification at time of BMT. The precise classification at transplantation was not reported in 11 patients. These were predominantly patients who had received chemotherapy prior to transplant conditioning. The disease stage, either untreated or after treatment with chemotherapy is given in Table 1 . The median interval between diagnosis and transplantation was 7 months (range 0-128 months). Patients were divided into early stage and more advanced stages depending on the stage of disease at transplantation. Patients with early stage (n = 26) are defined as untreated patients with RA, RARS or patients in first complete remission ( Table 2 ). The remaining patients were categorized as advanced disease (n = 47). Reporting of disease stage was absent for six patients. Patients with more advanced disease were equally likely to be transplanted with mismatched donors as patients treated in early stages of MDS ( Leukemia assumption, patients were subdivided into three age categories: Ͻ20 years (n = 27), 20-40 years (n = 26), and Ͼ40 years (n = 26). In addition, the patients were grouped together according to the following risk score: 0 points for patients with a donor without HLA-mismatches and with early stage of disease; 1 point for patients with a mismatched donor or advanced stage of disease; 2 points for patients with a mismatched donor and advanced stage of disease. Younger patients were more often transplanted in advanced disease stage, but age at transplantation did not correlate significantly with stage of disease, the degree of matching of the donor nor with the calculated risk score (Table 3) . The difference between the age groups and donor-patient relation was statistically significant. Parents were relatively more often the donors for the age group Ͻ20 years, siblings were more often the donors in patients aged 20-40 years, and other family members more often selected in patients older than 40 years (data not shown).
T cell depletion
Twenty-two patients received T cell-depleted grafts, and 46 patients received unmanipulated grafts. No information was available on 11 patients. T cell depletion was not applied more often in transplantation with mismatched donors.
Statistical analysis
Survival curves as well as curves for the relapse risk or TRM were calculated using the Kaplan-Meier method with date of transplant as starting point. Death was the event for survival. Patients were censored if alive at time of last follow-up. Relapse or death was the event for disease-free survival. Patients were censored if relapse-free and alive at time of last follow-up. The occurrence of relapse was the event for the estimation of relapse risk. Patients were either censored if relapse-free and alive at time of last follow-up or at time of death without relapse. Death without relapse was the event for TRM. Patients were censored at time of relapse or at time of last follow-up if alive without relapse. The log rank test was used for comparison of Kaplan-Meier curves. 
Results
Overall results
The median follow-up of the 79 patients in this study was 5 months (range 0-143 months). The median observation time of the 30 surviving patients was 22 months (range 1-143 months). Transplant-related complications were the cause of death in 35 of the 49 deceased patients. Most patients died within 1 year after transplantation, and no patient died beyond 18 months after transplantation. Survival, disease-free survival and transplant-related mortality were 35%, 31% and 62%, respectively at 3 years. The relapse risk was only 16% and no relapses occurred beyond 1 year after transplantation ( Figure 1 ). Engraftment occurred in 62 of the 79 patients. Eleven episodes of graft failure were seen. Six patients had insufficient information on engraftment. Grade 0 and grade I acute graft-versus-host disease (GVHD) occurred in 37 patients and grade I acute GVHD in 29 patients. Limited chronic GVHD occurred in 38 patients and extensive chronic GVHD in eight patients.
Prognostic factors
Recipient age did not influence the 3-year survival, diseasefree survival, relapse risk or transplant-related mortality. The 3-year survivals of patients in the three age groups were 37%, 42% and 25%, respectively, and the disease-free survivals were 29%, 40%, 24% respectively. The relapse risk was low in all three age groups and the transplant-related mortality was high irrespective of age (Table 4 ). The stage of disease at transplantation had a significant impact on survival and diseasefree survival which were significantly better for patients transplanted in an early phase of MDS at 49%, and 42% compared
Figure 1
Survival, disease-free survival (DFS), relapse risk and treatment-related mortality (TRM) of 79 patients with MDS transplanted with marrow from genotypically nonidentical family donors. to 31% and 28% 31% for patients transplanted in advanced stages. The risks of relapse and the transplant-related mortality were not significantly lower if the transplant was performed in an early stage of MDS, but both may have contributed to better survival and DFS of patients transplanted in an early phase ( Table 5 ). The superior survival of patients transplanted in an early phase of MDS was not due to younger age or the degree of HLA-matching, since the age distribution and the degree of HLA-matching was not different in both disease categories.
The overall survival, disease-free survival and treatment- related mortality was 57%, 52% and 36%, respectively, for patients transplanted with phenotypically matched family donors compared to 26%, 23% and 72% for those given cells from mismatched family donors (Table 6 ). The relapse risk was similar for both groups.
Comparison with other alternative forms of transplantation
The preferred curative treatment option for a young patient with MDS is allogeneic stem cell transplantation with a genotypically identical sibling donor. When no identical sibling donor is available three alternative options for stem cell transplantation exist: (1) allogeneic transplantation with stem cells from genotypically nonidentical donors; (2) allogeneic transplantation with stem cells from unrelated donors; and (3) autologous stem cell transplantation (ASCT). Therefore the results of transplantation with genotypically nonidentical donors have been compared with the two other treatment options.
Family donor transplantation vs autologous transplantation
The results of 20 patients transplanted in CR-1 with a genotypically nonidentical family donor have been compared with 75 patients autografted in CR-1 and matched for age at transplantation. Only patients transplanted in CR-1 have been compared since ASCT is preferentially performed in CR-1. The initial survival after ASCT was superior to the survival after family donor transplantation, but the survival after ASCT continued to decrease due to relapses. The 3-year survival after ASCT was 29%, and not significantly different from the 45% 3-year survival after family donor transplantation. The 3-year disease-free survival after ASCT was 31% and 37% after family donor transplantation. This difference is not statistically significant. The 3-year relapse risk was 57% after ASCT and 17% after family donor transplantation (P = 0.06). The 3-year transplant-related mortality is 55% for patients with family donor transplantation and 27% after ASCT (P = 0.005).
The results of transplantation with phenotypically identical family donors are better than those obtained with mismatched family donors. Therefore, the comparison of family donor transplantation with ASCT was repeated with the subgroup of 15 patients transplanted with mismatched family donors. The 3-year survival after mismatched family donor transplantation was 31% and 29% after ASCT (Figure 2 ). This difference is not statistically significant. The 3-year disease-free survival after transplantation with mismatched family donors was 22% and 31% after ASCT (P = 0.22). The 3-year relapse risk was 57% after ASCT and 31% after transplantation with mismatched 
Family donor transplantation vs unrelated donor transplantation
The second case-control study evaluated the results of 58 patients transplanted with mismatched family donors and 78 patients transplanted with unrelated donors, matched for stage of disease and age at transplantation. We excluded patients transplanted with phenotypically identical family donors because the results of this type of transplantation were better than those obtained with unrelated donors (Table 6 ). The 3-year survival for the patients with mismatched family donors was 26%, and 27% after unrelated donor transplantation (Figure 3) . The 3-year disease-free survival after mismatched family donor transplantation was 23% and 28% after transplantation with unrelated donors. The 3-year relapse risk of patients with mismatched donors was 18% and 29% for the patients with unrelated donors. The 3-year transplant-related mortality of the patients with mismatched family donors was 72% and 61% for the patients with unrelated donors.
Discussion
Transplantation with HLA-identical sibling donors is the treatment of choice for patients with MDS. 8, 10 A recent study of the EBMT showed a 5-year overall survival and disease-free survival of 41% and 34%, respectively, for 131 patients transplanted with HLA-identical sibling donors as first-line therapy. 10 The transplant-related mortality was 31% and the relapse risk was 39%. Younger age, shorter disease duration and a low percentage of marrow blasts (Ͻ5%) were associated with improved outcome. 11, 12 However, most patients lack a genotypically identical donor. This analysis evaluated the results of transplantation with genotypically non-identical related donors. The overall 3year survival after transplantation was 35% and the disease-free survival was 31%. The relapse risk of 16% was remarkably low, but the transplant-related mortality of 62% was high. Age is usually an important prognostic factor for the outcome after various forms of transplantation. [11] [12] [13] [14] However, age did not significantly affect the outcome of transplantation in this study. Younger patients were more often transplanted with mismatched donors and in advanced disease stages. These differences were not significant, but may have influenced the outcome ( Table 3 ). The stage of disease influenced survival and disease-free survival. Patients transplanted in an early phase had a better outcome than those transplanted in more advanced disease stages.
The 3-year disease-free survival of patients transplanted with phenotypically identical family donors was 57%. This was significantly superior to the 23% DFS of patients transplanted with mismatched family members. Therefore, transplantation with matched family donors is preferred over transplantation with mismatched family donors.
Autologous stem cell transplantation (ASCT) may be an alternative treatment option for MDS patients without an HLAidentical sibling donor. 9 A primary prerequisite for ASCT is complete remission with sufficient numbers of normal stem cells available for harvesting. Chemotherapy induces cytogenetically normal complete remissions in the majority of MDS patients 15 and long-term polyclonal remissions in some Comparison of survival, disease-free survival (DFS), relapse risk and treatment-related mortality (TRM) of 58 patients with MDS transplanted with marrow from genotypically nonidentical family donors and 78 matched patients transplanted with unrelated donors.
patients. 16 Moreover, the peripheral stem cell harvests of patients with MDS are usually polyclonal, when assessed by PCR techniques based on X-chromosome inactivation patterns. 17 Preliminary data indicate that repopulation after transplantation with mobilized peripheral stem cells is much faster compared to repopulation after autologous bone marrow transplantation. 18 The experience with ASCT in patients with MDS is limited and the follow-up is usually short. [19] [20] [21] [22] A recent analysis of 79 patients from the CLWP registry of the EBMT showed a 2-year DFS of 34%. 9 This was statistically significantly inferior to the DFS which was achieved for an age-matched group of patients transplanted in first remission for de novo AML. 9 In our study we compared the results of patients transplanted in first CR with autologous stem cells. The survival chances of both groups of patients were not statistically significant, but show a slightly better outcome for patients transplanted with a family donor. The TRM of patients transplanted with family donors was significantly higher than the TRM of patients after ASCT. In contrast, the relapse risk was higher after ASCT than after family donor transplantation. The decision to proceed to ASCT or alternative donor transplant must therefore depend on consideration of individual circumstances.
The development of efficient, world-wide registries of HLAtyped volunteer unrelated donors (VUD) has made allogeneic BMT with fully or partially matched unrelated donors a realistic alternative. Three recent analyses reported an 18 to 38% disease-free survival. 11, 23, 24 Non-relapse mortality was higher than that of HLA-identical related recipients. Factors that influenced outcome were age (younger age was associated with lower transplant-related mortality), blast count (early stage of disease was associated with lower relapse risk) and graft-versus-leukemia effect (patients with acute GVHD, grade II-IV had a lower relapse than patients without GVHD or grade I). 24 Our study showed a 3-year survival, DFS, relapse risk and TRM of 27%, 28%, 21% and 61% respectively, for the patients with unrelated donors. The patients transplanted with the mismatched family donors had a 3-year survival, DFS, relapse risk, and TRM of 26%, 23%, 18% and 72%, respectively. None of the four variables was significantly different between the patients transplanted with unrelated donors and those with mismatched family donors.
This analysis may provide some background and support to develop a treatment plan for MDS patients without a histocompatible sibling donor. First, transplantation with a phenotypically identical family donor (sibling, parent, cousin) gives similar results to transplantation with histocompatible sibling donors. Second, transplantation with nonidentical family members gives results not inferior to those obtained with matched unrelated donors. This implies that nonidentical family donors may be considered if a matched unrelated donor is not available. Third, if a MDS patient without a matched sibling is in first complete remission an autologous stem cell transplantation may be chosen. The disease-free survival is not inferior, and the intensity of the treatment is much lower. The decision may be influenced by the estimation of the relapse risk after autologous stem cell transplantation which may be higher in some patients. For instance, patients in morphological remission with persistent cytogenetic abnormalities are considered at high risk for relapse after autologous stem cell transplantation. Therefore, an allogeneic transplantation with a mismatched family member or a mismatched unrelated donor may be preferable.
